STOCK TITAN
  1. Home
  2. News
  3. CBAY

Cymabay Therapeutics Inc - CBAY STOCK NEWS

Welcome to our dedicated news page for Cymabay Therapeutics (Ticker: CBAY), a resource for investors and traders seeking the latest updates and insights on Cymabay Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cymabay Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cymabay Therapeutics's position in the market.

News
Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis
Rhea-AI Summary
CymaBay Therapeutics announces FDA's revised Breakthrough Therapy Designation for seladelpar in the treatment of primary biliary cholangitis (PBC)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
-
News
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Rhea-AI Summary
CymaBay Therapeutics announces late-breaking presentation on results from the RESPONSE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) at The Liver Meeting®
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
clinical trial
-
News
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
CymaBay Therapeutics grants inducement awards to two employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
News
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
Rhea-AI Summary
CymaBay Therapeutics initiates AFFIRM study to evaluate seladelpar's effect on clinical outcomes in patients with PBC. Study aims to confirm benefit of seladelpar over a 3-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
clinical trial
-
News
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
Rhea-AI Summary
CymaBay to participate in Cantor Global Healthcare Conference on September 27th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
conferences
-
News
CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
CymaBay Therapeutics closes underwritten public offering, raising approximately $258.7 million. Proceeds to be used for seladelpar development and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
offering
News
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
CymaBay Therapeutics announces pricing of public offering of common stock and pre-funded warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
offering
-
News
CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
CymaBay Therapeutics announces underwritten public offering of $150 million of common stock and pre-funded warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
offering
-
News
CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
Rhea-AI Summary
CymaBay announces positive Phase 3 results for seladelpar in PBC, meeting primary and key secondary endpoints. 61.7% of patients on seladelpar achieved primary composite endpoint vs. 20.0% on placebo. Normalization of alkaline phosphatase at 12 months achieved by 25.0% on seladelpar vs. 0% on placebo. Reduction in pruritus observed with seladelpar treatment. Safety and tolerability comparable between groups. Advancement to regulatory discussions and filing for approval planned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
clinical trial
News
CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
Rhea-AI Summary
CymaBay Therapeutics to announce topline results from Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC) in investor call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
conferences clinical trial
Stock CBAY logo
Cymabay Therapeutics Inc

Nasdaq:CBAY

CBAY Rankings

N/A Ranked by Market Cap
#14 Ranked by Stock Gains
N/A Ranked by Dividends

CBAY Stock Data

3.73B
96.64M
0.52%
103.13%
5.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newark

About CBAY

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.